Optimal LentiCRISPR-Based System for Sequential CRISPR/Cas9 Screens.


Journal

ACS synthetic biology
ISSN: 2161-5063
Titre abrégé: ACS Synth Biol
Pays: United States
ID NLM: 101575075

Informations de publication

Date de publication:
15 07 2022
Historique:
pubmed: 30 6 2022
medline: 19 7 2022
entrez: 29 6 2022
Statut: ppublish

Résumé

The advent of genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screening has advanced the understanding of molecular systems within cells. Here, we demonstrate the utility of sequentially performed CRISPR knockout screens that use an existing library to explore a biological question across the human genome, and then the remaining cells are used to examine each gene candidate against one common gene of interest. We call this approach "Many vs One" CRISPR screening, made possible by a modified 7SK promoter in place of the U6 promoter to drive expression of a single guide RNA. Inserting this novel 7SK promoter into the ubiquitously used lentiCRISPRv2 backbone is crucial, because it overcomes the need for a substantial increase in CRISPR library coverage during screening, sample processing, and next generation sequencing. This new 7SK vector equals the original lentiCRISPRv2 in lentiviral titer, knockout efficiency, and ease of use.

Identifiants

pubmed: 35767740
doi: 10.1021/acssynbio.2c00152
pmc: PMC9802680
mid: NIHMS1856032
doi:

Substances chimiques

RNA, Guide 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2259-2266

Subventions

Organisme : NCI NIH HHS
ID : P01 CA022443
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009135
Pays : United States

Références

G3 (Bethesda). 2017 Aug 7;7(8):2719-2727
pubmed: 28655737
Nat Biotechnol. 2016 Feb;34(2):184-191
pubmed: 26780180
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8245-50
pubmed: 9653172
Transcription. 2017;8(5):275-287
pubmed: 28598252
Nucleic Acids Res. 2014 Oct 29;42(19):e147
pubmed: 25122746
Nature. 2018 Nov;563(7733):646-651
pubmed: 30405244
Nat Biotechnol. 2019 Mar;37(3):224-226
pubmed: 30809026
Nat Commun. 2019 Sep 19;10(1):4284
pubmed: 31537810
Science. 2014 Jan 3;343(6166):80-4
pubmed: 24336569
Nat Biotechnol. 2018 Feb;36(2):179-189
pubmed: 29251726
Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13157-62
pubmed: 25157128
Cold Spring Harb Perspect Biol. 2013 Jan 01;5(1):a013029
pubmed: 23284049
Cell. 1987 Oct 9;51(1):81-7
pubmed: 3652210
Nat Genet. 2017 Feb;49(2):193-203
pubmed: 27992415
PLoS Pathog. 2016 Jun 30;12(6):e1005701
pubmed: 27362483
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903

Auteurs

Rebecca L Hutcheson (RL)

McArdle Laboratory for Cancer Research, University of Wisconsin─Madison, 1111 Highland Ave., Madison, Wisconsin 53705, United States.

Mitchell Hayes (M)

McArdle Laboratory for Cancer Research, University of Wisconsin─Madison, 1111 Highland Ave., Madison, Wisconsin 53705, United States.

Bill Sugden (B)

McArdle Laboratory for Cancer Research, University of Wisconsin─Madison, 1111 Highland Ave., Madison, Wisconsin 53705, United States.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH